Yahoo · Oct 13, 2026
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.
OM
NASDAQ · OMCL
Omnicell, Inc.
Healthcare · Medical - Healthcare Information Services
$36.65
Down-$0.23 (-0.62%)
Updated Oct 31, 2026, 10:16 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.01B
- P/E ratio
- 100.65
- Dividend yield
- 0.00%
- 52-week range
- $31.75 – $48.06
- Volume
- 785.54K
- Avg. volume
- 457.67K
Price performance · OMCL
OMCL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
OMCL closed at $36.65 after 21 trading sessions, up 9.08% for the selected period.
- Last close
- $36.65
- Period change
- +9.08%
- Period low
- $33.60
- Period high
- $37.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $37.07 | $37.30 | $35.50 | $36.65 | 785.54K |
| Oct 29, 2026 | $35.95 | $38.50 | $35.50 | $36.88 | 841.79K |
| Oct 28, 2026 | $36.83 | $37.50 | $35.45 | $35.95 | 936.99K |
| Oct 27, 2026 | $36.94 | $37.85 | $36.49 | $36.76 | 581.01K |
| Oct 26, 2026 | $37.73 | $37.83 | $36.75 | $36.97 | 539.74K |
| Oct 23, 2026 | $36.87 | $37.825 | $36.60 | $37.75 | 754.72K |
| Oct 22, 2026 | $36.40 | $37.64 | $36.3432 | $37.10 | 428.86K |
| Oct 21, 2026 | $36.07 | $37.21 | $35.585 | $36.34 | 459.09K |
| Oct 20, 2026 | $36.10 | $36.80 | $36.01 | $36.49 | 444.76K |
| Oct 19, 2026 | $35.39 | $36.195 | $35.1237 | $35.81 | 426.26K |
| Oct 16, 2026 | $36.12 | $36.5199 | $35.075 | $35.39 | 426.76K |
| Oct 15, 2026 | $35.45 | $36.2325 | $35.23 | $35.95 | 393.01K |
| Oct 14, 2026 | $36.13 | $36.41 | $35.07 | $35.39 | 385.75K |
| Oct 13, 2026 | $37.02 | $37.32 | $36.05 | $36.45 | 400.77K |
| Oct 12, 2026 | $35.87 | $37.17 | $35.59 | $36.87 | 459.04K |
| Oct 9, 2026 | $35.25 | $36.045 | $35.17 | $35.82 | 303.07K |
| Oct 8, 2026 | $34.89 | $35.06 | $34.425 | $34.83 | 509.48K |
| Oct 7, 2026 | $35.05 | $35.935 | $34.9101 | $35.21 | 570.64K |
| Oct 6, 2026 | $34.95 | $35.56 | $34.2401 | $35.46 | 634.25K |
| Oct 5, 2026 | $33.07 | $34.72 | $33.07 | $34.64 | 397.67K |
| Oct 2, 2026 | $33.93 | $33.96 | $33.41 | $33.60 | 344.5K |
Latest OMCL news
The latest Smart Investors Daily articles mentioning OMCL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
OMCL research
Overview
Company profile and research snapshot.
Company profile
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $55.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | Freedom Capital Markets | Buy | — |
| Aug 3, 2026 | Piper Sandler | Overweight | — |
| Jul 31, 2026 | Wells Fargo | Overweight | — |
| Jul 31, 2026 | Keybanc | Overweight | — |
| Apr 29, 2026 | Keybanc | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 8, 2026
Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
FORT WORTH, Texas, October 08, 2026--Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
Yahoo · Oct 7, 2026
Does Omnicell’s Revenue Beat and Weak EBITDA Guidance Change The Bull Case For OMCL?
In the recent past, Omnicell reported quarterly revenue of US$312.2 million, a 7.4% year-on-year increase that slightly exceeded analysts’ expectations, while issuing EBITDA guidance for the next quarter that fell well short of market forecasts. This combination of stronger-than-expected sales and weaker profitability outlook highlights a tension between revenue momentum and margin pressure in Omnicell’s current business performance. We’ll now examine how Omnicell’s weaker EBITDA guidance,...
Yahoo · Oct 6, 2026
1 Healthcare Stock with Exciting Potential and 2 We Find Risky
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 40.7% over the past six months, topping the S&P 500 by 23.9 percentage points.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
